Movmedix Leverages FDA Clearance to Launch Revolutionary LARS® Technology in the US Market

Movmedix Breaks New Ground in the U.S. Orthopedic Market

In a significant milestone for orthopedic health solutions, French company Movmedix has announced its entry into the U.S. market, following FDA clearance for its innovative LARS® ACJ system. This synthetic ligament platform, acknowledged worldwide, revolutionizes approaches to surgical ligament rehabilitation and repair. With this expansion, Movmedix aims to address the growing public health issue posed by ligament injuries that affect countless individuals, especially athletes.

The LARS® ACJ System: A Technological Breakthrough

The LARS® ACJ implant, constructed from biocompatible polyethylene terephthalate (PET), represents the third generation of synthetic implants designed to offer stabilization during the healing stage after syndesmotic trauma, such as acromioclavicular separations caused by disruptions in the coracoclavicular ligament. It comes equipped with specialized screws and surgical instruments tailored for performance optimization.

This new FDA clearance is momentous, not merely because it sanctions an advanced device for acromioclavicular joint (ACJ) injuries, but it heralds the arrival of a well-established synthetic ligament technology in the United States. For over three decades, LARS® has been instrumental in ligament reconstruction and reinforcement across various anatomical territories, now boasting over 11 clinical indications and having aided more than 250,000 patients globally.

Addressing a Growing Health Concern

Ligament injuries have emerged as one of the leading health challenges in the musculoskeletal domain, particularly in the U.S., where over 200,000 anterior cruciate ligament (ACL) injuries are documented annually, impacting primarily young athletes and military personnel. These injuries can lead to extensive rehabilitation periods and significantly heighten lifetime risks for diseases like osteoarthritis, which collectively impose substantial financial burdens on the healthcare system.

Interestingly, acromioclavicular joint dislocations constitute 10% of all shoulder injuries and are particularly common among athletes in contact sports, exemplifying the urgent need for advanced treatment options.